Press Release Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity 5 hours ago
Press Release Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights Aug 5